What are the treatment options for locally advanced Bladder Cancer

Treatment Options for Locally Advanced Bladder Cancer

Locally advanced bladder cancer (typically Stage III disease) has several established treatment approaches. Let me walk you through how doctors think about this and what options exist.

How Doctors Approach Locally Advanced Bladder Cancer

According to NCCN Guidelines, locally advanced bladder cancer is generally defined as disease that has invaded the muscle layer of the bladder (T2-T4a) and may involve nearby lymph nodes (N1-N3). The key clinical decision is whether to pursue bladder-preserving approaches (keeping your bladder) or radical cystectomy (surgical removal of the bladder).

---

Main Treatment Approaches

1. Radical Cystectomy (Surgical Removal)

This is the traditional standard approach for locally advanced disease:

• What it involves: Complete surgical removal of the bladder, surrounding tissues, and nearby lymph nodes
• When it's used: Often recommended as the primary treatment for fit patients without extensive complications
• Reconstruction: After removal, surgeons create a new way for urine to leave your body (called a urinary diversion)

Perioperative Chemotherapy (chemotherapy given around the time of surgery):

• Neoadjuvant chemotherapy (before surgery): Cisplatin-based chemotherapy given first to shrink the tumor, then surgery follows. This approach has shown improved survival outcomes.
• Adjuvant chemotherapy (after surgery): Given if high-risk features are found in the surgical specimen (like stage pT3, pT4a, or positive lymph nodes)

---

2. Bladder-Preserving Chemoradiotherapy (Trimodality Therapy)

This is an important alternative that allows you to keep your bladder:

The Three Components:

1. TURBT (Transurethral Resection of Bladder Tumor) - An endoscopic procedure to remove as much visible tumor as possible
2. Radiation therapy - Targeted radiation to the bladder and surrounding area
3. Concurrent chemotherapy - Usually cisplatin given at the same time as radiation to enhance effectiveness

Key Points About Bladder Preservation:

• According to NCCN Guidelines, this approach is endorsed by major international organizations (ICUD-EAU, NICE, AUA/ASCO/ASTRO/SUO)
• 5-year survival rates are comparable to cystectomy in selected patients (approximately 49% in major trials)
• Best candidates have:
  • Smaller, solitary tumors
  • No extensive or multifocal carcinoma in situ (CIS)
  • No moderate/severe hydronephrosis (kidney swelling)
  • Good bladder function before treatment
  • Ability to tolerate cisplatin chemotherapy

Important Consideration: Studies show that up to 45% of bladders may be clinically understaged after initial TURBT, meaning some residual disease might remain. This is why complete TURBT is critical before starting chemoradiotherapy.

---

3. Systemic Chemotherapy for Node-Positive Disease

For patients with clinically positive lymph nodes (Stage IIIB: cN1-N3):

Downstaging Chemotherapy:

• Cisplatin-based chemotherapy given first to shrink lymph node involvement
• Effectiveness: Studies show that induction chemotherapy achieves complete pathologic downstaging in:
  • 39% of patients with single positive node (cN1)
  • 27% of patients with multiple positive nodes (cN2-N3)
• After chemotherapy response, patients may then proceed to cystectomy or chemoradiotherapy

Chemoradiotherapy Alternative:

• Concurrent chemoradiotherapy is another option for node-positive disease
• Research shows patients treated with chemoradiotherapy had better median overall survival (19.0 months) compared to chemotherapy alone (13.8 months)

---

4. Adjuvant Immunotherapy

After surgery, newer immunotherapy options may be considered:

• Nivolumab or pembrolizumab (checkpoint inhibitors) - FDA-approved for patients with high-risk features after cystectomy
• These are considered if:
  • No neoadjuvant chemotherapy was given AND you have pT3, pT4a, or positive nodes, OR
  • Neoadjuvant chemotherapy was given AND you still have ypT2-ypT4a or positive nodes after surgery

---

Key Factors Your Doctor Will Consider

According to NCCN Guidelines, your treatment recommendation depends on:

✓ Tumor characteristics: Size, location, depth of invasion, presence of CIS
✓ Lymph node status: Whether nodes are involved
✓ Your kidney function: Ability to tolerate cisplatin (measured by GFR - glomerular filtration rate)
✓ Your overall health: Comorbidities and performance status
✓ Bladder function: How well your bladder works before treatment
✓ Your preferences: Whether you want to preserve your bladder if possible

---

Questions to Ask Your Oncology and Urology Team

1. Based on my specific tumor stage and characteristics, which approach do you recommend for me—cystectomy or bladder preservation?

2. If bladder preservation is an option, what are the specific pros and cons for my case, and what is the expected success rate?

3. Am I a candidate for cisplatin-based chemotherapy? (This requires checking kidney function)

4. If I choose cystectomy, will I receive neoadjuvant chemotherapy before surgery, and what are the benefits?

5. What happens if the initial treatment doesn't work completely? What are my options then?

6. What side effects should I expect from each treatment option, and how will they affect my quality of life?

7. Are there clinical trials available for my stage of disease?

---

Important Reminders

The NCCN Guidelines emphasize that locally advanced bladder cancer is a complex disease requiring individualized treatment planning. Your specific situation—including your tumor's exact characteristics, your overall health, kidney function, and personal preferences—will determine the best approach for you.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.